Fungal vaccines

References

• Chowdhary A, Sharma C, Meis JF. Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216:S436–44.
   PubMed Web of Science ®Google Scholar
• Hokken MWJ, Zoll J, Coolen JPM, et al. Phenotypic plasticity and the evolution of azole resistance in Aspergillus fumigatus; An expression profile of clinical isolates upon exposure to itraconazole. BMC Genomics. 2019;20. DOI:https://doi.org/10.1186/s12864-018-5255-z
   Google Scholar
• MSD Animal Health Hub: Bovilis® Ringvac. n.d. NOAH Compendium. Bovilis-Ringvac. [cited 2021 Apr 17]. https://www.noahcompendium.co.uk/?id=-476795
   Google Scholar
• Levitz SM. Aspergillus vaccines: hardly worth studying or worthy of hard study? Med Mycol. 2017;55:103–108.
   PubMed Web of Science ®Google Scholar
• Medici NP, Poeta MD. New insights on the development of fungal vaccines: from immunity to recent challenges. Mem Inst Oswaldo Cruz. 2015;110:966–973.
   PubMed Web of Science ®Google Scholar
• McEwen SA, Fedorka‐Cray PJ. Antimicrobial use and resistance in animals. Clin Infect Dis. 2002;34:93–106.
   PubMed Web of Science ®Google Scholar
• Leading International Fungal Education Invasive fungal infections. LIFE 2015. [cited 2021 Apr 17]. life-worldwide.org/fungal-diseases/invasive/
   Google Scholar
• Kischkel B, Rossi SA, Santos SR, et al. Therapies and vaccines based on nanoparticles for the treatment of systemic fungal infections. Front Cell Infect Microbiol. 2020;10. DOI:https://doi.org/10.3389/fcimb.2020.00463
   Google Scholar
• Taborda CP, Nosanchuk JD. Editorial: vaccines, immunotherapy and new antifungal therapy against fungi: updates in the new frontier. Front Microbiol. 2017;8:1743.
   PubMed Web of Science ®Google Scholar
• Spellberg B. Vaccines for invasive fungal infections. F1000 Med Rep. 2011;3:13.
   PubMedGoogle Scholar
• Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007;45:321–346.
   PubMed Web of Science ®Google Scholar
• Ito JI, Lyons JM, Diaz-arevalo D, et al. Vaccine progress. Med Mycol. 2009;47:394–400.
   PubMed Web of Science ®Google Scholar
• Bozza S, Gaziano R, Lipford GB, et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 2002;4:1281–1290.
   PubMed Web of Science ®Google Scholar
• Liu M, Clemons KV, Bigos M, et al. Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine. 2011;29:1745–1753.
   PubMed Web of Science ®Google Scholar
• Diaz-Arevalo D, Bagramyan K, Hong T, et al. CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect Immun. 2011;79:2257–2266.
   PubMed Web of Science ®Google Scholar
• Stuehler C, Khanna N, Bozza S, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011;117:5881–5891.
   PubMed Web of Science ®Google Scholar
• Torosantucci A, Bromuro C, Chiani P, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med. 2005;202:597–606.
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Bacci A, et al. Vaccination in mice with invasive pulmonary aspergillosis. J Immunol. 2000;165:381–388.
   PubMed Web of Science ®Google Scholar
• Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood. 2003;102:3807–3814.
   PubMed Web of Science ®Google Scholar
• Ito JI, Lyons JM. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis. 2002;186:869–871.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Danielson ME, Michel KS, et al. Whole glucan particles as a vaccine against murine aspergillosis. J Med Microbiol. 2014;63:1750–1759.
   PubMed Web of Science ®Google Scholar
• Ito JI, Lyons JM, Hong TB, et al. Vaccinations with recombinant variants of allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun. 2006;74:5075.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Iannitti RG, et al. Host defense pathways against fungi: the basis for vaccines and immunotherapy. Front Microbiol. 2012;3. DOI:https://doi.org/10.3389/fmicb.2012.00176
   Google Scholar
• Romani L. Cell mediated immunity to fungi: a reassessment. Med Mycol. 2008;46:515–529.
   PubMed Web of Science ®Google Scholar
• Zelante T, Bozza S, De Luca A, et al. Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol. 2009;47:S162–9.
   PubMed Web of Science ®Google Scholar
• Cassone A, Casadevall A. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol. 2012;15:427–433.
   PubMed Web of Science ®Google Scholar
• Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007;37:2695.
   PubMed Web of Science ®Google Scholar
• Latgé JP, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin Microbiol Rev. 2019;33:e00140–18.
   PubMed Web of Science ®Google Scholar
• Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med. 2007;57:552–556.
   Google Scholar
• Kim H, Park H, Lee SJ. Effective method for drug injection into subcutaneous tissue. Sci Rep. 2017;7:9613.
   PubMed Web of Science ®Google Scholar
• Özen M, Dündar NO. Invasive aspergillosis in children with hematological malignancies. Expert Rev Anti Infective Infect Ther. 2011;9:299–306.
   PubMed Web of Science ®Google Scholar
• Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–2738.
   PubMed Web of Science ®Google Scholar
• Edwards JE. Fungal cell wall vaccines: an update. J Med Microbiol. 2012;61:895–903.
   PubMed Web of Science ®Google Scholar
• Cutler JE, Deepe GS, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol. 2007;5:13–28.
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:1–13.
   PubMed Web of Science ®Google Scholar
• Wüthrich M, Ersland K, Sullivan T, et al. Fungi subvert vaccine T cell priming at the respiratory mucosa by preventing chemokine-induced influx of inflammatory monocytes. Immunity. 2012;36:680–692.
   PubMed Web of Science ®Google Scholar
• Chai LYA, Van De Veerdonk F, Marijnissen RJ, et al. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology. 2010;130:46–54.
   PubMed Web of Science ®Google Scholar
• Stevens DA. Th1/Th2 in aspergillosis. Med Mycol. 2006;44:229–235.
   Web of Science ®Google Scholar
• Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining Lymph nodes and initiate disparate Th responses to the fungus. J Immunol. 2002;168:1362–1371.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Calich VLG, Burger E, et al. Pathogenesis I: interactions of host cells and fungi. Med Mycol. 2000;38:99–111.
   PubMed Web of Science ®Google Scholar
• Mencacci A, Perruccio K, Bacci A, et al. Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood. 2001;97:1483–1490.
   PubMed Web of Science ®Google Scholar
• Nagai H, Guo J, Choi H, et al. Interferon-γ and tumor necrosis factor-α protect mice from invasive aspergillosis. J Infect Dis. 1995;172:1554–1560.
   PubMed Web of Science ®Google Scholar
• Wüthrich M, Filutowicz HI, Warner T, et al. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med. 2003;197:1405–1416.
   PubMed Web of Science ®Google Scholar
• Nanjappa SG, Heninger E, Wüthrich M, et al. Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog. 2012;8:24.
   Web of Science ®Google Scholar
• Cenci E, Mencacci A, Casagrande A, et al. Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin‐6–deficient mice with invasive pulmonary aspergillosis. J Infect Dis. 2001;184:610–617.
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells in vivo: a Key target for a new vaccine science. Immunity. 2008;29:319–324.
   PubMed Web of Science ®Google Scholar
• Young JW, Merad M, Hart DNJ. Dendritic cells in transplantation and immune-based therapies. Biol Blood Marrow Transplant. 2007;13:23–32.
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366.
   PubMed Web of Science ®Google Scholar
• Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329–368.
   PubMed Web of Science ®Google Scholar
• Chu RS, Targoni OS, Krieg AM, et al. CpP oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997;186:1623–1631.
   PubMed Web of Science ®Google Scholar
• Nierman WC, Pain A, Anderson MJ, et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature. 2005;438:1151–1156.
   PubMed Web of Science ®Google Scholar
• Santos E, Levitz SM. Fungal vaccines and immunotherapeutics. Cold Spring Harb Perspect Med. 2014;4:a019711-a019711.
   PubMed Web of Science ®Google Scholar
• Zepp F. Principles of vaccine design-Lessons from nature. Vaccine. 2010;28:C14–24.
   PubMed Web of Science ®Google Scholar
• Specht CA, Nong S, Dan JM, et al. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis. 2007;196:796–800.
   PubMed Web of Science ®Google Scholar
• Yuan R, Casadevall A, Oh J, et al. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci U S A. 1997;94:2483–2488.
   PubMed Web of Science ®Google Scholar
• Roilides E, Katsifa H, Walsh TJ. Pulmonary host defences against Aspergillus fumigatus. Res Immunol. 1998;149: 454–465.
   PubMedGoogle Scholar
• Cenci E, Mencacci A, Casagrande A, et al. Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J Infect Dis. 2001;184:610–617.
   PubMed Web of Science ®Google Scholar
• Krylov VB, Nifantiev NE. Synthetic carbohydrate based anti-fungal vaccines. Drug Discov Today Technol. 2020;35–36:35–43.
   PubMedGoogle Scholar
• Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine. 2014;32:327–337.
   PubMed Web of Science ®Google Scholar
• Kischkel B, Rossi SA, Santos SR, et al. Therapies and vaccines based on nanoparticles for the treatment of systemic fungal infections. Front Cell Infect Microbiol. 2020;10:463.
   PubMed Web of Science ®Google Scholar